Acadia Pharma (ACAD) Misses Q2 EPS by 14c
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $26.40 -3.26%
Revenue Growth %: +19.3%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Revenue Growth %: +19.3%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.63), $0.14 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $97 thousand versus the consensus estimate of $90 thousand.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Super Micro Computer rises on AI server market optimism
- Evercore lifts Ciena rating on AI-driven optical networking boom
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
